Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients

Am J Nephrol. 1998;18(5):416-21. doi: 10.1159/000013386.

Abstract

It has been reported that cumulative carnitine losses through dialysis membranes may worsen hyperlipidemia during long-term hemodialysis. However, carnitine supplementation has not shown a consistent beneficial response. We undertook the present study to determine if there is any hypolipidemic effect of L-carnitine on Greek dialysis patients in concert with the dialysate buffer composition (acetate or bicarbonate). A total of 28 patients (16 male, 12 female), mean age 43 years (range 21-61), with end-stage renal disease on maintenance hemodialysis for a mean period of 25 months (range 7-84) were studied. The dialysis schedule was 4 h, 3 times/week using cuprophane hollow-fiber dialyzers and acetate (n = 14) or bicarbonate (n = 14) dialysate. In all patients L-carnitine (5 mg/kg body weight) was infused intravenously 3 times/week at the end of each hemodialysis session. Blood samples for carnitine and lipid determinations were obtained before treatment, and 3 and 6 months following treatment. Even though L-carnitine did not modify most of the serum lipid levels, a significant decrease in serum triglycerides was evident in the whole group of patients (from 225 +/- 76 to 201 +/- 75 mg/dl, p = 0.03). Furthermore, L-carnitine could decrease serum triglycerides only in hypertriglyceridemic patients (from 260 +/- 64 to 226 +/- 82 mg/dl, p < 0.05). L-Carnitine resulted in a reduction of serum triglycerides in both patients on bicarbonate and on acetate dialysis, while there were no significant differences in the changes of lipid parameters after L-carnitine between the two groups of hemodialysis patients. We conclude that relatively low doses of L-carnitine supplementation could contribute to the management of some hypertriglyceridemic hemodialysis patients.

MeSH terms

  • Adult
  • Apolipoproteins / blood
  • Buffers
  • Carnitine / administration & dosage*
  • Carnitine / blood
  • Cholesterol / blood
  • Female
  • Hemodialysis Solutions
  • Humans
  • Hypertriglyceridemia / drug therapy
  • Hypertriglyceridemia / etiology
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy
  • Lipids / blood*
  • Lipoproteins / blood
  • Male
  • Middle Aged
  • Renal Dialysis*
  • Triglycerides / blood

Substances

  • Apolipoproteins
  • Buffers
  • Hemodialysis Solutions
  • Lipids
  • Lipoproteins
  • Triglycerides
  • Cholesterol
  • Carnitine